Register Login

CABALETTA BIO, INC. (CABA)

SymbolCABA
NameCABALETTA BIO, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address2929 ARCH STREET,SUITE 600, PHILADELPHIA, Pennsylvania, 19104, United States
Telephone+1 267 759-3100
Fax—
Email—
Websitehttps://www.cabalettabio.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001759138
Description

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.

Additional info from NASDAQ:
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.

2026-07-23 18:28

New Form SCHEDULE 13G/A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001104659-26-086361 <b>Size:</b> 15 KB

Read more
2026-06-11 11:01

(99% Neutral) CABALETTA BIO, INC. (CABA) Announces Regulatory Update

Read more
2026-06-10 23:04

Tomasello Shawn 🟢 acquired 22.0K shares (1 derivative) of Cabaletta Bio, Inc. (CABA) at $3.22 Transaction Date: Jun 09, 2026 | Filing ID: 266239

Read more
2026-06-10 22:59

Simon Mark 🟢 acquired 22.0K shares (1 derivative) of Cabaletta Bio, Inc. (CABA) at $3.22 Transaction Date: Jun 09, 2026 | Filing ID: 266232

Read more
2026-06-10 22:56

HENRIQUES RICHARD C JR 🟢 acquired 22.0K shares (1 derivative) of Cabaletta Bio, Inc. (CABA) at $3.22 Transaction Date: Jun 09, 2026 | Filing ID: 266229

Read more
2026-06-10 22:54

Bollard Catherine 🟢 acquired 22.0K shares (1 derivative) of Cabaletta Bio, Inc. (CABA) at $3.22 Transaction Date: Jun 09, 2026 | Filing ID: 266224

Read more
2026-06-10 22:51

Brun Scott C. 🟢 acquired 22.0K shares (1 derivative) of Cabaletta Bio, Inc. (CABA) at $3.22 Transaction Date: Jun 09, 2026 | Filing ID: 266220

Read more
2026-06-05 15:10

New Form SCHEDULE 13G/A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001137774-26-000127 <b>Size:</b> 7 KB

Read more
2026-06-04 17:18

New Form SCHEDULE 13G/A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-06-04 <b>AccNo:</b> 0000053417-26-000042 <b>Size:</b> 6 KB

Read more
2026-06-03 11:02

(30% Negative) CABALETTA BIO, INC. (CABA) Announces Delay in included Trials for 2H27 myositis BLA submission Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Read more